This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
By Luisa Sterkel & Joana Loureiro , Tenthpin Consultants The promise and potential of cell and gene therapies (CGT) has emerged in the recent past and currently over 1.500 CGT are registered for clinicaltrials holding great hope for the treatment of challenging and uncurable diseases.
Despite their exciting potential, the smooth operation of cell therapy development trials requires extraordinary orchestration, perfectly aligning the product and patient journeys. While clinicalsupply is essential to any successful trial, autologous cell therapy trials occupy the far end of the spectrum regarding risk tolerance.
Modern software development concepts from ecommerce applications are helping eClinical applications meet the precise needs of each clinicaltrial. IRT solutions help clinicaltrial sponsors meet the complexities of patient randomization and clinicalsupply management. until the database lock of the system.
Randomization and TrialSupply Management (RTSM) play a pivotal role in the successful execution of clinicaltrials. As the complexity of clinicaltrials continues to increase, especially with the rise of multi-center, adaptive, and decentralized trials, the need for robust RTSM systems has become more critical than ever.
Avoiding “Customs Chaos” in ClinicalTrials Means Working Closely with Your Importer of Record Many global clinicaltrial shipments get muddled regarding the critical role and responsibilities of the importer of record (IOR) for clinicaltrials.
Avoiding “Customs Chaos” in ClinicalTrials Means Working Closely with Your Importer of Record Many global clinicaltrial shipments get muddled regarding the critical role and responsibilities of the importer of record (IOR) for clinicaltrials.
Food and Drug Administration (FDA) has granted Fast Track designation to VTX-801, Vivet’s clinical-stage gene therapy for the treatment of Wilson Disease – a rare, genetic disorder that reduces the ability of the liver and other tissues to regulate copper levels, causing severe hepatic damage, neurological symptoms, and potentially death.
Data is the single most important thing in a clinicaltrial. The data serves as the cornerstone for critical decisions determining the fate of therapies and the performance of trials. The data highlights fast or slow recruitment and how the drug supply is managed. Simply put, it’s the story of the trial.
Data is the single most important thing in a clinicaltrial. The data serves as the cornerstone for critical decisions determining the fate of therapies and the performance of trials. The data highlights fast or slow recruitment and how the drug supply is managed. Simply put, it’s the story of the trial.
Data is the single most important thing in a clinicaltrial. The data serves as the cornerstone for critical decisions determining the fate of therapies and the performance of trials. The data highlights fast or slow recruitment and how the drug supply is managed. Simply put, it’s the story of the trial.
Data is the single most important thing in a clinicaltrial. The data serves as the cornerstone for critical decisions determining the fate of therapies and the performance of trials. The data highlights fast or slow recruitment and how the drug supply is managed. Simply put, it’s the story of the trial.
In clinical research, Cepharanthine exhibits multiple pharmacological properties including anti-oxidative, anti-inflammatory, immuno-regulatory, anti-cancer, anti-viral and anti-parasitic properties. Sairiyo is currently focused on advancing the clinical development of Cepharanthine to treat rare cancer diseases.
XTALKS WEBINAR: Fostering Patient-Centricity: ClinicalSupply Chain Strategies and Sourcing Solutions Live and On-Demand: Thursday, July 20, 2023, at 10am EDT (4pm CEST/EU-Central) Register for this free webinar to learn how to review clinicaltrial trends and supply strategies that impact the patient experience.
Africa has considerable advantages and opportunities for trialling investigational medicinal products that, if pharma companies can correctly harness, will turn the continent into a superpower for clinicaltrials. Clinicaltrials data for Africa Globally, research has found that 62.2% being African American, 3.4%
We organize all of the trending information in your field so you don't have to. Join 21,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content